Tecovirimat for the Treatment of Mpox

Karen P. Acker; William A. Fischer; Lu Zheng; C. McCarthy; Pooja T. Saha; Arzhang Cyrus Javan; Sasha W. Tilles; Matthew M. Hamill; Kieron Leslie; Kristina M. Brooks; Jonathan Berardi; Wanting He; Lara A. Hosey; Grace M. Aldrovandi; Kathie G. Ferbas; Cheryl L. Day; Rachel A. Bender Ignacio; Robert Bolan; Pablo Tebas; Wairimu Chege; Anne F. Luetkemeyer; Juan Sierra Madero; R. Gandhi; Sharon Nachman; Joe J Eron; Pat Flynn; Timothy J. Wilkin

doi:10.1056/nejmoa2506495

Key Points

This research aims to evaluate the efficacy of tecovirimat in treating adults with mpox.
Conducted a clinical trial to assess tecovirimat therapy.
Included adults diagnosed with clade II mpox.
Measured outcomes such as time to clinical resolution, pain levels, and viral clearance.
No evidence that tecovirimat therapy shortened time to clinical resolution.

Implication

Trial demonstrates no benefit of tecovirimat treatment for clinical resolution and pain in adults with mpox, suggesting limited effectiveness.

Abstract

This trial showed no evidence that tecovirimat therapy shortened the time to clinical resolution, reduced pain, or increased viral clearance among adults with clade II mpox. (Funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; STOMP/A5418 ClinicalTrials.gov number, NCT05534984.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Acker et al. (2026) studied this question.

synapsesocial.com/papers/69a285da0a974eb0d3c00cd5 https://doi.org/10.1056/nejmoa2506495

View Full Paper

Ask AI

Bookmark

Share

Tecovirimat for the Treatment of Mpox

Key Points

Implication

Abstract

Discussion

Cite This Study

Tecovirimat for the Treatment of Mpox

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading